Table of Contents
ISRN Hematology
Volume 2012 (2012), Article ID 943089, 5 pages
Research Article

Angiogenesis in Non-Hodgkin's Lymphoma: An Intercategory Comparison of Microvessel Density

1Department of Pathology, Hindu Rao Hospital, Malka Ganj, Delhi 110007, India
2Department of Pathology, Chacha Nehru Bal Chikitsalaya, Geeta Colony, Delhi 110031, India
3Department of Medicine, Hindu Rao Hospital, Malka Ganj, Delhi 110007, India

Received 29 November 2011; Accepted 10 January 2012

Academic Editor: E. Balleari

Copyright © 2012 Deepti Aggarwal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. This study was aimed at comparing angiogenesis, seen as microvessel density (MVD) in subtypes of non-Hodgkin’s lymphoma (NHL). Methods. In this study, 64 cases of NHL diagnosed over a three-year period were included along with 15 lymph node biopsies of reactive hyperplasia. NHLs were classified using REAL classification, and immunohistochemistry was performed for CD34 in all cases. CD34-stained sections were evaluated for “hot spots,” where MVD was assessed and expressed as per mm2. Appropriate statistical methods were applied. Results. There were 6 cases of well-differentiated lymphocytic lymphoma (SLL), 21 diffuse large B-cell lymphoma (DLBCL), 15 follicular lymphoma, 10 lymphoblastic lymphoma, 7 MALToma, and 5 peripheral T-cell lymphoma (PTCL). Mean MVD was highest in reactive hyperplasia ( 1 9 1 . 9 2 ± 1 2 . 1 6 per mm2) compared to all NHLs. Among NHLs, PTCL demonstrated the highest MVD ( 1 8 3 . 4 2 ± 8 . 2 4 ) followed by DLBCL ( 1 4 9 . 9 1 ± 1 3 . 6 8 ). A significant difference was found in MVD between reactive and individual lymphoma groups. SLL had significantly lower MVD than other lymphoma subtypes. Conclusion. Angiogenesis, assessed by MVD, showed significant differences among subtypes of NHL, especially the indolent types like SLL. The higher MVD in aggressive lymphomas like PTCL and DLBCL can potentially be utilized in targeted therapy with antiangiogenic drugs.